Dormant viruses re-emerge in patients with lingering sepsis, signaling immune suppression

The data show the rate of viral conversion for septic patients whose blood or plasma initially tested negative for virus and who subsequently became positive during the course of their sepsis. The time is in days after patients met the criteria for a diagnosis of sepsis. Of the septic patients, overall 24 percent were positive for CMV, 53 percent for EBV, 14 percent for HSV, 10 percent for HHV-6 and 78 percent for TTV. Abbreviations: Cytomegalovirus, CMV; Epstein-Barr virus, EBV; HSV, herpes simplex viruses 1 and 2; HHV-6, human herpes virus 6; Torque teno virus, TTV. Credit: PLoS ONE 9(6): e98819. doi:10.1371/journal.pone.0098819

A provocative study links prolonged episodes of sepsis—a life-threatening infection and leading cause of death in hospitals—to the reactivation of otherwise dormant viruses in the body.

In healthy people, such latent are kept in check by the . But a study by a team at Washington University School of Medicine in St. Louis provides strong evidence that when sepsis lingers for more than a few days, which is common, viruses re-emerge and enter the bloodstream, signaling that the immune system has become suppressed. This state of immune suppression may leave unable to fight off secondary infections, such as pneumonia associated with being on a ventilator.

The research, published June 11 in PLOS One, suggests that drugs that "rev up" the immune system could be incorporated into the treatment of prolonged sepsis.

"A controversy has existed over whether patients with sepsis progress to a state of immune suppression," said co-senior author Gregory Storch, MD, a virologist and chief of the Division of Pediatric Infectious Diseases. "The finding that with sepsis have a number of different viruses circulating in the bloodstream is compelling evidence they are immune-suppressed and dramatically could alter therapy for sepsis."

Surprisingly, the researchers detected levels of viruses in sepsis patients that were on par with those seen in patients who have had organ transplants and are taking immune-suppression drugs to prevent rejection.

"This is an indicator of the degree of immune suppression in septic patients, and it tells us they are highly immune-suppressed," explained senior author Richard S. Hotchkiss, MD, professor of anesthesiology.

More than 200,000 patients in the United States die annually of sepsis. The condition develops when the body mounts a massive immune response to infection, triggering excessive inflammation that can lead quickly to organ failure. While some patients die soon after the condition develops, most sepsis deaths occur four or more days after onset.

"We've gotten much better at getting sepsis patients through the initial phase," said Hotchkiss, who also is a professor of medicine and of surgery. "But too many patients die several weeks or months after sepsis sets in, primarily of secondary infections."

Earlier research at Washington University and other institutions has hinted that lingering sepsis may be linked to . But a lack of compelling evidence has kept the debate going.

For the current study, first authors Andrew Walton and Jared Muenzer, MD, used polymerase chain reaction (PCR) testing to detect a range of viruses in blood and urine samples from 560 critically ill patients with sepsis, who were treated in the surgical and medical intensive care units at Barnes-Jewish Hospital. As a comparison, they performed the same test on 161 critically ill patients in the hospital who did not have sepsis and 164 healthy patients who were having outpatient surgery.

"We were looking for viruses that people are commonly exposed to early in life and that persist in the body in a latent form that doesn't cause sickness," said Storch, the Ruth L. Siteman Professor of Pediatrics. "No one had really looked at this in a comprehensive fashion before. These viruses have the potential to reactivate if the immune system is suppressed."

Patients with lingering sepsis had markedly higher levels of viruses detectable in the blood, compared with the healthy controls and critically ill patients without sepsis. Among the sepsis patients, for example, the researchers found that 53 percent had Epstein-Barr virus, 24 percent had cytomegalovirus, 14 percent had herpes-simplex virus, and 10 percent had human herpes simplex virus-7.

These viruses generally don't lead to significant illness in people who are healthy but can cause problems in patients who are immune-suppressed.

The researchers noted that 43 percent of patients with sepsis had two or more viruses detected in their blood or urine during their hospital stays. However, this finding may underestimate the frequency of viral infections because some of these patients were not tested for all viruses. In a subgroup of 209 sepsis patients tested for all viruses, 54 percent were positive for two or more.

Additionally, the researchers found that septic patients with higher levels of viruses detected in their blood were more likely than critically ill patients without sepsis to have more severe illnesses, secondary fungal and bacterial infections, and longer stays in the intensive care unit.

Also, septic patients with evidence of cytomegalovirus in plasma, a component of blood, had significantly higher 90-day death rates than septic patients who tested negative for the virus, although it is not clear whether the cytomegalovirus contributed to the additional deaths.

"We stumbled onto more viruses than we expected, and we don't know yet whether some of these viruses are causing problems in their own right," Storch said. "We think this paper will stimulate others to carry out further investigations of the role of latent viruses in sepsis."

A further direction for researchers is to determine whether PCR testing for a panel of latent viruses could be used as a readout of the state of a person's immunity. If this is the case, doctors could perform PCR testing in patients with cancer, autoimmune diseases and infections and use results to guide treatments.

The findings also open the door to new ways of treating sepsis. Over the years, a number of treatments have been evaluated to treat sepsis, but none has worked well. The new research indicates that, in addition to using powerful antibiotics to fight off infections in patients with sepsis, immunotherapy drugs that boost the immune system may be an effective therapy. The Washington University team is planning several clinical trials of such drugs in patients in the near future.

More information: Walton AH, Muenzer JT, Rasche D, Boomer JS, Sato B, et al. (2014) Reactivation of Multiple Viruses in Patients with Sepsis. PLoS ONE 9(6): e98819. doi:10.1371/journal.pone.0098819 . dx.plos.org/10.1371/journal.pone.0098819

add to favorites email to friend print save as pdf

Related Stories

Sepsis involved in high percentage of hospital deaths

May 18, 2014

An analysis that included approximately 7 million hospitalizations finds that sepsis contributed to 1 in every 2 to 3 deaths, and most of these patients had sepsis at admission, according to a study published by JAMA. The st ...

New perspective on sepsis

Apr 17, 2014

In a review published in the April issue of Immunity, Kevin J. Tracey, MD, president of The Feinstein Institute for Medical Research, says it's time to take a fresh look at the medical community's approach to treating sepsis ...

Recommended for you

Research reveals how lymph nodes expand during disease

Oct 22, 2014

Cancer Research UK and UCL scientists have discovered that the same specialised immune cells that patrol the body and spot infections also trigger the expansion of immune organs called lymph nodes, according to a study published ...

Protecting us from our cells

Oct 22, 2014

Our immune system defends us from harmful bacteria and viruses, but, if left unchecked, the cells that destroy those invaders can turn on the body itself, causing auto-immune diseases like type-1 diabetes ...

User comments